Hypothesis

P2X<sub>7</sub> Receptors as a Transducer in the Co-Occurrence of Neurological/Psychiatric and Cardiovascular Disorders: A Hypothesis

Stephen D. Skaper and Pietro Giusti

Department of Pharmacology and Anesthesiology, University of Padova, Largo “E.Meneghetti” 2, 35131 Padova, Italy

Correspondence should be addressed to Stephen D. Skaper, stephen.skaper@unipd.it

Received 23 May 2009; Accepted 19 June 2009

Recommended by Hari Manev

Background. Over-stimulation of the purinergic P2X<sub>7</sub> receptor may bring about cellular dysfunction and injury in settings of neurodegeneration, chronic inflammation, as well as in psychiatric and cardiovascular diseases. Here we speculate how P2X<sub>7</sub> receptor over-activation may lead to the co-occurrence of neurological and psychiatric disorders with cardiovascular disorders. Presentation. We hypothesize that proinflammatory cytokines, in particular interleukin-1β, are key players in the pathophysiology of neurological, psychiatric, and cardiovascular diseases. Critically, this premise is based on a role for the P2X<sub>7</sub> receptor in triggering a rise in these cytokines. Given the broad distribution of P2X<sub>7</sub> receptors in nervous, immune, and vascular tissue cells, this receptor is proposed as central in linking the nervous, immune, and cardiovascular systems. Testing. Investigate, retrospectively, whether a bidirectional link can be established between illnesses with a proinflammatory component (e.g., inflammatory and chronic neuropathic pain) and cardiovascular disease, for example, hypertension, and whether patients treated with anti-inflammatory drugs have a lower incidence of disease complications. Positive outcome would indicate a prospective study to evaluate therapeutic efficacy of P2X<sub>7</sub> receptor antagonists. Implications. It should be stressed that sufficient direct evidence does not exist at present supporting our hypothesis. However, a positive outcome would encourage the further development of P2X<sub>7</sub> receptor antagonists and their application to limit the co-occurrence of neurological, psychiatric, and cardiovascular disorders.

Copyright © 2009 S. D. Skaper and P. Giusti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Background

The P2X<sub>7</sub> receptor (P2X<sub>7</sub>R) was originally described in cells of hematopoietic origin, and mediates the influx of Ca<sup>2+</sup> and Na<sup>+</sup> ions as well as the release of proinflammatory cytokines. P2X<sub>7</sub>Rs may affect cell death through their ability to regulate the processing and release of interleukin-1β (IL-1β), a key mediator in neurodegeneration, chronic inflammation, and, perhaps, some psychiatric diseases [1]. There is now ample evidence that elevated IL-1β levels, associated in many cases with P2X<sub>7</sub>-R activation, occur in Alzheimer’s disease, spinal cord injury, proinflammatory tissue trauma, neuropathic pain, and depressive illness. Preliminary, albeit intriguing observations suggest that elevated blood pressure may be associated with polymorphic variations in the P2X<sub>7</sub>R gene. Collectively, these findings have led us to propose a hypothesis in which the P2X<sub>7</sub>R is viewed as a common transducer of communication between the nervous, immune, and cardiovascular systems, whereby receptor over-activation may lead to the co-occurrence of neurological and psychiatric disorders with cardiovascular disorders, and vice versa.

2. Presentation of the Hypothesis

2.1. P2X<sub>7</sub>R as a Transducer in the Co-Occurrence of Neurological/Psychiatric and Cardiovascular Disorders. ATP-sensitive P2X<sub>7</sub>Rs are localized on cells of hematopoietic lineage including mast cells, erythrocytes, monocytes, peripheral macrophages, dendritic cells, T- and B-lymphocytes, epidermal Langerhans cells, and glial cells in the CNS [2, 3]. Activation of P2X<sub>7</sub>Rs leads to rapid changes in intracellular calcium concentrations, release of the proinflammatory cytokine...
IL-1β and following prolonged exposure, the formation of cytotoxic pores in plasma membranes. P2X7Rs could affect IL-1β also via the 5-lipoxigenase pathway; that is, P2X7R activation leads to leukotriene formation (e.g., in astrocytes) [4] and leukotrienes increase IL-1β expression and release [5]. Both the localization and functional consequences of P2X7R activation indicate a role in inflammatory processes. Activated immune cells (lymphocytes) [6], macrophages [7], microglia [8], and platelets [9], and dying cells may release high concentrations of ATP into the extracellular space [10], while extracellular ATP concentrations increase under inflammatory conditions in vivo [11] and in response to tissue trauma [12]. In addition, pro-inflammatory cytokines and bacterial products upregulate P2X7R expression and increase its sensitivity to extracellular ATP [13].

We hypothesize that pro-inflammatory cytokines, in particular IL-1β, are key players in the pathophysiology of neurological, psychiatric, and cardiovascular diseases. Critically, this premise is based on a role for the P2X7-R in triggering a rise in these cytokines. One of the most striking features of ATP is its unmatched ability to promote massive release of mature IL-1β from lipopolysaccharide primed mononuclear phagocytes and other cell types, including microglia [14]. ATP-driven maturation and release of IL-1β are specifically mediated by the P2X7 receptor for extracellular ATP [15, 16]. Given the broad distribution of P2X7-Rs in nervous, immune, and vascular tissue cells, this receptor is proposed as playing a common transductional role in linking the nervous, immune, and cardiovascular systems. We also hypothesize that P2X7-R over-activation may lead to the co-occurrence of neurological and psychiatric disorders with cardiovascular disorders (Figure 1).

These speculative hypotheses are based on an extensive body of published studies describing pro-inflammatory cytokine elevations and P2X7-R over-activity in neurodegenerative diseases, pain, depression, and cardiovascular disease. Activation of P2X7-Rs provides an inflammatory stimulus [17], and P2X7R-deficient mice have substantially attenuated inflammatory responses [15, 18]. Acute spinal cord injuries produce highly inflammatory environments [19]. In rats subjected to spinal cord injury, areas surrounding the traumatic lesion displayed an abnormally high and sustained pattern of ATP release, and delivery of a P2X7-R antagonist after acute impact injury improved functional recovery and diminished cell death in the peritraumatic zone [20]. P2X7R-like immunoreactivity was upregulated around β-amyloid plaques in a transgenic mouse model of Alzheimer’s disease, and was regionally localized with activated microglia and astrocytes [21]. Up-regulation of P2X7-Rs on microglia is seen after ischemia in the cerebral cortex of rats [22], and on reactive astrocytes in multiple sclerosis autopsy brain tissue [23]. Genetic and pharmacological approaches have been used to show that P2X7-R activation on microglia is necessary for microglial cell-mediated injury of neurons [24].

Phenotypic data from P2X7-R null mice provide important evidence for participation of this channel in pro-inflammatory tissue trauma. There is a lower incidence and severity of collagen antibody-induced arthritis in P2X7-R knockout mice [25], and inflammatory and neuropathic hypersensitivity is completely absent to both mechanical and thermal stimuli in these mice [18]. Moreover, P2X7-R is upregulated in human dorsal root ganglia and injured nerves obtained from chronic neuropathic pain patients [18]. Endogenous IL-1 levels are increased in the nervous system.
in response to trauma associated with mechanical damage, ischemia, seizures, and hyperexcitability [26].

There appears to be a strong relationship between depression and immunological dysfunction in depressed patients [27]. Cytokines like IL-1β are suggested to be involved in the pathophysiology of depression, and excessive secretion of macrophage cytokines (IL-1β, tumor necrosis factor-α, interferon-γ) could be a potential causative factor [28]. Central and systemic administration of proinflammatory cytokines to animals induces “sickness behavior,” which is characterized by many of the physiological and behavioral changes associated with depression [27, 29]. Clinical use of cytokines (e.g., interferon-α) produces depressive-like symptoms that can be attenuated with antidepressant treatment [30], and major depressive illness is associated with significant elevations in the density of microglia and hypersecretion of proinflammatory cytokines, suggesting that the latter could be involved in the etiopathogenesis of depression [31–34].

Apoptotic cell death occurs in a number of vascular diseases, including atherosclerosis and hypertension [35]. Shear stress that occurs during changes in blood flow causes a substantial release of ATP from vascular endothelial cells [36]. ATP may also be released from cardiomyocytes in ischemic or hypoxic conditions [37]. P2X7R-associated production of proinflammatory cytokines like tumor necrosis factor-α could promote endothelial cell apoptosis [34], and play a role in vascular remodeling in hypertension [38]. P2X7 receptor channels are involved in transducing aldosterone-mediated signaling in the distal renal tubule and are potential candidate genes for blood pressure regulation [39]. On an intriguing note, there is evidence to suggest that elevated nighttime diastolic blood pressure is associated with single nucleotide polymorphisms of the P2X7 gene [40]. P2X7Rs are expressed in human saphenous vein myocytes [41], and venous diseases may favor conditions allowing P2X7R activation and lysis of venous myocytes. ATP released after hypoxia, stress and inflammation, or membrane damage, conditions found in the vessel wall of varicose veins, may lead to P2X7R-induced pore formation, the disorganization and loss of contractile myocytes in the muscle layers of the media of varicose veins, and venous disease.

Fibroblasts are a key structural element of the arterial wall known to play a major role in atherosclerosis and diabetic angiopathy [42]. Fibroblasts from type-2 diabetes patients are characterized by a hyperactive purinergic loop [43].

3. Testing the Hypothesis

Retrospective studies inform us, for example, that depression is recognized as having high prevalence in several medical conditions including infectious, autoimmune, and neurodegenerative diseases, conditions associated with a proinflammatory status [28, 44]. Increasing evidence now points to a strong relationship between depression and immunological dysfunction in depressed patients, while clinical use of cytokines produces depressive-like symptoms responsive to antidepressant treatment [30]. While depression and cardiovascular comorbidity have been recognized for some time [45], a proinflammatory link has only recently been investigated [46]. Although a first step, these correlations are not definitive proof of our concept. More extensive prospective studies are required to confirm the above, and to investigate whether a link exists between illnesses with a proinflammatory component (e.g., inflammatory and chronic neuropathic pain) and cardiovascular disease, for example, hypertension, and whether patients treated with anti-inflammatory drugs have a lower incidence of cardiovascular complications. This would then need to be followed with a demonstration that pharmacological block of P2X7Rs provides therapeutic benefit in these conditions.

4. Implications of the Hypothesis

If a strong link between neurological, psychiatric and, cardiovascular disorders could be established, then within this framework P2X7R activity can be viewed as playing a common transductional (“gatekeeper”) role in the development of comorbidity between the nervous, immune, and cardiovascular systems. The outcome, if positive, would provide the impetus for further development and clinical application of selective and potent P2X7R antagonists.

References

[1] S. D. Skaper, P. Debetto, and P. Giusti, “P2X7 receptors in neurological and cardiovascular disorders,” Cardiovascular Psychiatry and Neurology. In press.
[2] R. A. North, “Molecular physiology of P2X receptors,” Physiological Reviews, vol. 82, no. 4, pp. 1013–1067, 2002.
[3] A. Surprenant, F. Rassendren, E. Kawashima, R. A. North, and G. Buell, “The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7),” Science, vol. 272, no. 5626, pp. 735–738, 1996.
[4] P. Ballerini, R. Cicarelli, F. Caciagli, et al., “P2X7 receptor activation in rat brain cultured astrocytes increases the biosynthetic release of cysteinyl leukotrienes,” International Journal of Immunopathology and Pharmacology, vol. 18, no. 3, pp. 417–430, 2005.
[5] E. Porreca, P. Conti, C. Feliciani, et al., “Cysteinyl-leukotriene D4 induced IL-1β expression and release in rat vascular smooth muscle cells,” Atherosclerosis, vol. 115, no. 2, pp. 181–189, 1995.
[6] A. Filippini, R. E. Taffs, T. Agui, and M. V. Sitkovsky, “Ecto-ATPase activity in cytolytic T-lymphocytes. Protection from the cytolytic effects of extracellular ATP,” Journal of Biological Chemistry, vol. 265, no. 1, pp. 334–340, 1990.
[7] A. Sikora, J. Liu, C. Brosnan, G. Buell, I. Chessell, and B. R. Bloom, “Cutting edge: purinergic signaling regulates radical-mediated bacterial killing mechanisms in macrophages through a P2X7-independent mechanism,” Journal of Immunology, vol. 163, no. 2, pp. 558–561, 1999.
[8] D. Ferrari, P. Chiozzi, S. Falzoni, et al., “ATP-mediated cytotoxicity in microglial cells,” Neuropharmacology, vol. 36, no. 9, pp. 1295–1301, 1997.
[9] R. Beigi, E. Kobatake, M. Aizawa, and G. R. Dubyak, “Detection of local ATP release from activated platelets using
cell surface-attached firefly luciferase," *American Journal of Physiology*, vol. 276, no. 1 45-1, pp. C267–C278, 1999.
[10] G. R. Dubyak and C. el-Moatassim, “Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides,” *The American Journal of Physiology*, vol. 265, no. 3, part 1, pp. C577–606, 1993.
[11] E. R. Lazarowski, R. C. Boucher, and T. K. Harden, “Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations,” *Journal of Biological Chemistry*, vol. 275, no. 40, pp. 31061–31068, 2000.
[12] K. Nieber, D. Eschke, and A. Brand, “Brain hypoxia: effects of ATP and adenosine,” *Progress in Brain Research*, vol. 120, pp. 287–297, 1999.
[13] B. D. Humphreys and G. R. Dubyak, “Modulation of P2X nucleotide receptor expression by pro- and anti-inflammatory stimuli in THP-1 monocytes,” *Journal of Leukocyte Biology*, vol. 64, no. 2, pp. 265–273, 1998.
[14] F. Di Virgilio, P. Chiozzi, D. Ferrari, et al., “Nucleotide receptors: an emerging family of regulatory molecules in blood cells,” *Blood*, vol. 97, no. 3, pp. 587–600, 2001.
[15] M. Solle, I. Labasi, D. G. Perregaux, et al., “Altered cytokine production in mice lacking P2X receptors,” *Journal of Biological Chemistry*, vol. 276, no. 1, pp. 125–132, 2001.
[16] D. Ferrari, C. Pizzirani, E. Adinolfi, et al., “The P2X receptor: a key player in IL-1 processing and release,” *Journal of Immunology*, vol. 176, no. 7, pp. 3877–3883, 2006.
[17] R. L. Feuvre, D. Brough, and N. Rothwell, “Extracellular ATP and P2X7 receptors in neurodegeneration,” *European Journal of Pharmacology*, vol. 447, no. 2–3, pp. 261–269, 2002.
[18] I. P. Chessell, J. P. Hatcher, C. Bountra, et al., “Disruption of the P2X purinoceptor gene abolishes chronic inflammatory and neuropathic pain,” *Pain*, vol. 114, no. 3, pp. 386–396, 2005.
[19] R. W. Keane, A. R. Davis, and W. D. Dietrich, “Inflammatory and apoptotic signaling after spinal cord injury,” *Journal of Neurotrauma*, vol. 23, no. 3–4, pp. 335–344, 2006.
[20] X. Wang, G. Arcuino, T. Takano, et al., “P2X receptor inhibition improves recovery after spinal cord injury," *Nature Medicine*, vol. 10, no. 8, pp. 821–827, 2004.
[21] L. K. Parvathenani, S. Tertyshnikova, C. R. Greco, S. B. Roberts, B. Robertson, and R. Posmantur, "P2X mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer’s disease," *Journal of Biological Chemistry*, vol. 278, no. 15, pp. 13309–13317, 2003.
[22] H. Franke, A. Günther, J. Grosche, et al., “P2X receptor expression after ischemia in the cerebral cortex of rats,” *Journal of Neurophysiology and Experimental Neurology*, vol. 63, no. 7, pp. 686–699, 2004.
[23] L. Narcisse, E. Scemes, Y. Zhao, S. C. Lee, and C. F. Brosnan, “The cytokine IL-1β transiently enhances P2X receptor expression and function in human astrocytes,” *GLIA*, vol. 49, no. 2, pp. 245–258, 2005.
[24] S. D. Skaper, L. Facci, A. A. Culbert, et al., “P2X receptors on microglial cells mediate injury to cortical neurons in vitro,” *GLIA*, vol. 54, no. 3, pp. 234–242, 2006.
[25] J. M. Labasi, N. Petrushova, C. Donovan, et al., “Absence of the P2X receptor alters leukocyte function and attenuates an inflammatory response,” *Journal of Immunology*, vol. 168, no. 12, pp. 6436–6445, 2002.
[26] O. Touzani, H. Boutin, J. Chuquet, and N. Rothwell, “Potential mechanisms of interleukin-1 involvement in cerebral ischaemia,” *Journal of Neuroimmunology*, vol. 100, no. 1–2, pp. 203–215, 1999.
[27] H. Anisman and Z. Merali, “Cytokines, stress, and depressive illness,” *Brain, Behavior, and Immunity*, vol. 16, no. 5, pp. 513–524, 2002.
[28] R. S. Smith, “The macrophage theory of depression,” *Medical Hypotheses*, vol. 35, no. 4, pp. 298–306, 1991.
[29] H. Anisman, Z. Merali, M. O. Poulter, and S. Hayley, “Cytokines as a precipitant of depressive illness: animal and human studies,” *Current Pharmaceutical Design*, vol. 11, no. 8, pp. 963–972, 2005.
[30] M. R. Kraus, A. Schäfer, H. Faller, H. Csef, and M. Scheurlen, “Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C,” *Alimentary Pharmacology and Therapeutics*, vol. 16, no. 6, pp. 1091–1099, 2002.
[31] J. Steiner, H. Bielau, R. Brisch, et al., “Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide,” *Journal of Psychiatric Research*, vol. 42, no. 2, pp. 151–157, 2008.
[32] M. Maes, “Major depression and activation of the inflammatory response system,” *Advances in Experimental Medicine and Biology*, vol. 461, pp. 25–46, 1999.
[33] C. Tüglo, S. H. Kara, O. Caliyurt, E. Vardar, and E. Abay, “Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder,” *Psychopharmacology*, vol. 170, no. 4, pp. 429–433, 2003.
[34] S. Alesci, P. E. Martinez, S. Kelkar, et al., “Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications,” *Journal of Clinical Endocrinology and Metabolism*, vol. 90, no. 5, pp. 2522–2530, 2005.
[35] Z. Mallat and A. Tedgui, “Aptosis in the vasculature: mechanisms and functional importance,” *British Journal of Pharmacology*, vol. 130, no. 5, pp. 947–962, 2000.
[36] G. Burnstock, “Release of vasoactive substances from endothelial cells by shear stress and purinergic mechanosensory transduction," *Journal of Anatomy*, vol. 194, no. 3, pp. 335–342, 1999.
[37] A. K. Dutta, R. Z. Sabirov, H. Uramoto, and Y. Okada, “Role of ATP-conductive anion channel in ATP release from neonatal rat cardiomyocytes in ischaemic or hypoxic conditions,” *Journal of Physiology*, vol. 559, no. 3, pp. 799–812, 2004.
[38] G. H. Gibbons, “Autocrine-paracrine factors and vascular remodeling in hypertension," *Current Opinion in Nephrology and Hypertension*, vol. 2, no. 2, pp. 291–298, 1993.
[39] Y. Zhang, D. Sanchez, J. Gorelik, et al., “Basolateral P2X-like receptors regulate the extracellular ATP-stimulated epithelial Na+ channel activity in renal epithelia," *American Journal of Physiology*, vol. 292, no. 6, pp. F1734–F1740, 2007.
[40] J. Palomino-Doza, T. I. Rahman, P. J. Avery, et al., “Ambulatory blood pressure is associated with polymorphic variation in P2X receptor genes," *Hypertension*, vol. 52, no. 5, pp. 980–985, 2008.
[41] C. Cario-Toumaniartz, G. Loirand, A. Ladoux, and P. Pacaud, “P2X receptor activation-induced contraction and lysis in human saphenous vein smooth muscle," *Circulation Research*, vol. 83, no. 2, pp. 196–203, 1998.
[42] E. Duner, F. Di Virgilio, R. Trevisan, M. R. Cipollina, G. Crepaldi, and R. Nosadini, “Intracellular free calcium abnormalities in fibroblasts from non-insulin-dependent diabetic patients with and without arterial hypertension," *Hypertension*, vol. 29, no. 4, pp. 1007–1013, 1997.
pathogenetic mechanism for vascular damage in diabetes,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 24, no. 7, pp. 1240–1245, 2004.

[44] M. Maes, “Evidence for an immune response in major depression: a review and hypothesis,” *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, vol. 19, no. 1, pp. 11–38, 1995.

[45] A. H. Glassman, “Depression and cardiovascular comorbidity,” *Dialogues in Clinical Neuroscience*, vol. 9, no. 1, pp. 9–17, 2007.

[46] J. C. Stewart, K. L. Rand, M. F. Muldoon, and T. W. Kamarck, “A prospective evaluation of the directionality of the depression-inflammation relationship,” *Brain, Behavior, and Immunity*. In press.